Host immune response in returning travellers infected with malaria by Gregory MacMullin et al.
MacMullin et al. Malaria Journal 2012, 11:148
http://www.malariajournal.com/content/11/1/148RESEARCH Open AccessHost immune response in returning travellers
infected with malaria
Gregory MacMullin1,2, Ronald Mackenzie1,3, Rachel Lau1, Julie Khang4, Haibo Zhang3,4, Nimerta Rajwans5,
W Conrad Liles3,5 and Dylan R Pillai6*Abstract
Background: Clinical observations suggest that Canadian-born (CB) travellers are prone to more severe malaria,
characterized by higher parasite density in the blood, and severe symptoms, such as cerebral malaria and renal
failure, than foreign-born travellers (FB) from areas of malaria endemicity. It was hypothesized that host cytokine and
chemokine responses differ significantly in CB versus FB patients returning with malaria, contributing to the courses
of severity. A more detailed understanding of the profiles of cytokines, chemokines, and endothelial activation may
be useful in developing biomarkers and novel therapeutic approaches for malaria.
Materials and methods: The patient population for the study (n = 186) was comprised of travellers returning to
Toronto, Canada between 2007 and 2011. The patient blood samples’ cytokine, chemokine and angiopoietin
concentrations were determined using cytokine multiplex assays, and ELISA assays.
Results: Significantly higher plasma cytokine levels of IL-12 (p40) were observed in CB compared to FB travellers,
while epidermal growth factor (EGF) was observed to be higher in FB than CB travellers. Older travellers (55 years
old or greater) with Plasmodium vivax infections had significantly higher mean cytokine levels for IL-6 and
macrophage colony-stimulating factor (M-CSF) than other adults with P. vivax (ages 18–55). Patients with P. vivax
infections had significantly higher mean cytokine levels for monocyte chemotactic protein-1 (MCP-1), and M-CSF
than patients with Plasmodium falciparum. Angiopoietin 2 (Ang-2) was higher for patients infected with
P. falciparum than P. vivax, especially when comparing just the FB groups. IL-12 (p40) was higher in FB patients with
P. vivax compared to P. falciparum. Il-12 (p40) was also higher in patients infected with P. vivax than those infected
with Plasmodium ovale. For patients travelling to West Africa, IFN-γ and IL-6 was lower than for patients who were
in other regions of Africa.
Conclusion: Significantly higher levels of IL-12 (p40) and lower levels of EGF in CB travellers may serve as useful
prognostic markers of disease severity and help guide clinical management upon return. IL-6 and M-CSF in older
adults and MCP-1, IL-12 (p40) and M-CSF for P. vivax infected patients may also prove useful in understanding
age-associated and species-specific host immune responses, as could the species-specific differences in Ang-2.
Regional differences in host immune response to malaria infection within the same species may speak to unique
strains circulating in parts of West Africa.
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Almost half the global population is at risk of contracting
malaria, with 300–500 million new clinical cases arising
each year that result in between one and three million
deaths [1,2]. In countries where malaria is non-endemic,
the parasite can still have a significant impact on the popu-
lation and its healthcare system. When travellers visit mal-
aria endemic regions, especially when visiting friends and
relatives (VFR), there is a significant risk of the disease
being imported into a non-endemic country [3,4]. Each
year, approximately 10,000–30,000 travellers from industria-
lized nations are expected to contract malaria, and the
number is continuing to increase [5]. Toronto, Ontario has
a population of 2.48 million people (5.5 million in the
Greater Toronto Area), with half of the inhabitants having
been born outside Canada [6]. In addition to the large
population, over 16 million people visit the city each year
[7]. The substantial immigrant population and associated
factors create significant potential for malaria cases to occur
in the region, despite it being non-endemic.
Severe malaria is defined by the WHO as a situation
in which a patient suffering from asexual parasitaemia,
with no other obvious causes of symptoms, has one or
more clinical or laboratory features that include but are
not limited to hyperparasitaemia, impaired conscious-
ness or unrousable coma, renal impairment, and pros-
tration [8,9]. Severe malaria is most often seen in
Plasmodium falciparum-infected patients, but has been
seen, defined under the same criteria, in Plasmodium
vivax-infected patients [9]. Clinical observations of
Canadian-born (CB) travellers suggest they are prone
to more severe malaria compared to foreign-born (FB)
travellers[10]. It was hypothesized that cytokine, che-
mokine, and endothelial activation responses would
differ significantly between CB and FB travelling
patients returning with malaria, as more severe cases of
malaria often have characteristically different immune
response profiles [11-13]. To address this hypothesis,
cytokine, chemokine, and expression of the endothelial
activation marker angiopoietin-1/2 (Ang-1/2) was
quantified based on CB and FB status, gender, age group,
country of travel, and species of Plasmodium (P. vivax, P.
falciparum, Plasmodium malariae and Plasmodium ovale)
infection. The resulting data was analysed to identify im-
mune factors associated with disease severity, and other
patient sample characteristics.Methods
Ethics approval
The study acquired ethics approval from the Toronto
Academic Health Sciences Network Research Ethics
Board (REB#10-0094-E).Study population and patient inclusion criteria
The malaria specimen database at Public Health Ontario
Laboratories (PHOL) comprises patient blood samples
received for analysis between 2006 and 2011 coupled to
basic patient information. Samples from patients suspected
to have malaria were obtained via venipuncture by physi-
cians from hospitals and clinics throughout the Greater
Toronto Area and transported to PHOL in EDTA vacutai-
ner (BD) tubes for processing in the clinical parasitology
department. Following sample analysis using Giemsa-
stained thin and thick smear microscopy, in vitro immuno-
chromatographic assays (BinaxNow, Inverness Medical),
and quantitative PCR as required, samples positive for mal-
aria were transferred to molecular research for storage and
further analysis.
Only samples with complete demographic information,
defined as patient age, gender, parasitaemia, country of
birth and species of infection, were selected for the study.
The sample set was stratified into patients born in Canada,
and those who recently immigrated to Canada from mal-
aria endemic regions. The samples from CB patients were
considered to be more likely to have severe malaria, as
defined by WHO guidelines and the RIFLE criteria for
acute renal failure [8,9]. An approximately even number of
males and females were selected, with a distribution of ages
and parasitaemia. Samples were selected from patients
infected with each of the four malaria parasites, generating
four distinct sample sets to study. A total of 186 patient
samples were analysed in this study. Detailed sample infor-
mation is depicted in Table 1.
Sample processing and storage
After homogenization through repeated inversions,
specimens delivered to Public Health Ontario, which
were positive for P. vivax, P. ovale, and P. malariae
were immediately transferred into 110μL whole-blood
aliquots. The aliquots were stored in 0.5 mL screw
top tubes at −80°C. Specimens positive for P. falcip-
arum were first separated into two approximately
equal aliquots after homogenizing. One aliquot was
further separated into cellular and plasma fractions
via centrifugation at 2,000 rpm for 5 min. The plasma
fraction and the remaining whole blood aliquot were
separated into 110 μL volumes and stored at −80°C in
the same manner as the other Plasmodium spp.
Patient samples arrived at PHOL along with specimen
data sheets filled out by their attending doctor specifying
age, gender, travel history, and other personal data. Clinical
parasitology test results confirmed species, immunochro-
matography test results, parasitaemia (parasites/1,000 cells
counted), and microscopy as well as PCR observations.
The data was de-linked from the patients’ names and other
personal identifiers, and the remaining details were added
Table 1 Detailed sample information, broken down by
species of infection, Canadian-born or foreign-born
status, sex and gender
P. falciparum P. vivax P. ovale P. malariae
n= 103 n = 60 n = 14 n= 9
Canadian-born 54 12 1 2
Sex
Male 34 9 0 0
Female 20 3 1 2
Age
0–18 6 0 0 0
19–55 38 9 1 2
55+ 10 3 0 0
Foreign-born
(Recent immigrant)
49 48 13 7
Sex
Male 18 26 9 5
Female 31 22 4 2
Age
0–18 12 8 1 0
19–55 30 26 11 6
55+ 7 15 1 1
Table 1 - Sample Set Information.
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men data sheet being placed under lock and key for refer-
ence. Follow-ups with the patients’ physicians by the
medical microbiologist occasionally provided more specific
patient information.
Samples selected for use in the study required add-
itional processing prior to being used in the assays. All P.
falciparum samples designated for use in the experiment
were from plasma aliquots. The aliquots were removed
from −80°C storage, and thawed on ice until they were
ready for aspiration. The samples were then separated
into two 55μL aliquots and placed back in −80°C storage
until required for assays.
Whole-blood samples of P. vivax, P. ovale, and P.
malariae were removed from −80°C storage and after
thawing on ice, treated with lysis buffer in order to iso-
late the plasma fraction. This step was required because
repeated freeze/thawing of the blood at −80°C leads to
some cell lysis, releasing haemoglobin into the plasma
fraction and inhibiting proper separation by pipetting
and visible plasma fraction. To ensure the samples con-
tained no intact erythrocytes, they were incubated in
ACK lysing buffer (Invitrogen) at a ratio of 10:1 sample
to buffer volume for 3 min at room temperature. This
step was followed by centrifugation of the samples at 4°
C and 2,000 rpm for 5 min. Following this, the super-
natant was removed and stored in 55μL aliquots back at
−80°C until required for assays.The prepared samples were transported to collabora-
tors on dry ice and immediately placed at −80°C upon
arrival.Cytokine multiplex assay
Based on prior studies that established a link either in vitro
or in vivo with malaria infection, 20 cytokines were selected
to evaluate in this study [11-19]. These included; GM-CSF,
IFN-γ, IL-1b, IL-2, IL-4, IL-6, IL-8, IL-10, TNF, IL-12(p70),
MCP-1, IL-5, TGF-α, TGF-β, IL-12(p40), IL-13, IL-17-α,
EGF, M-CSF, and IFN-β. Cytokine quantification was con-
ducted using the ProcartaW Cytokine Assay Kit (Affymetrix,
Santa Clara, CA, USA) [20]. The final concentrations of
cytokine and chemokines are reported in pg/mL.Angiopoietin-1/2 ELISA assay
Based on prior studies establishing a link between severe
malaria and angiopoietins, Ang-1 and Ang-2 were also
evaluated [12,19].
To do this, 96-well plates were coated with 50 μl of
capture antibody (R&D; Ang-1: cat. DY923, Ang-2: cat.
DY623) per well and left to incubate overnight at room
temperature. Plates were then washed seven times with
0.05% Tween-20 in PBS pH 7.2–7.4, and blotted on
paper towel. Two hundred μl of reagent diluent (PBS pH
7.2–7.4/0.1% BSA mixture) was then applied to each well
and left to incubate for 2 h. Afterwards, the diluent was
drained and 100 μl of standard solution (R&D; part
940685) diluted in reagent diluent was applied to stand-
ard wells at the top of the standard lanes. The remaining
wells in the standards lane were filled with standards
serially diluted, so that each well contained half the con-
centration of standards compared to the well above it,
with the last lane containing only reagent diluent. The
remaining wells were filled with 50 μl of sample diluted
at a ratio of 1:5. The plates were then left to incubate at
4°C overnight.
Ninety-six-well plates were then washed seven times
with 0.05% Tween-20 in PBS pH 7.2–7.4, and blotted on
paper towel. Fifty μl of detection antibody (R&D: part
840684) reconstituted in reagent diluent was then ap-
plied to each well and left to incubate for 2 h at room
temperature. Plates were then washed seven times with
0.05% Tween-20 in PBS pH 7.2–7.4, and then blotted on
paper towel. Fifty μl of extravidin alkaline phosphatase
(Sigma; cat. E2636) that was diluted 1:1,000 in reagent
diluent was applied to each well and left to incubate for
45 min at room temperature. Plates were washed an-
other seven times with 0.05% Tween-20 in PBS pH 7.2–
7.4, then rinsed with distilled water and blotted on paper
towel. One hundred μl of PNPP Sigma fast (Sigma; cat.
N2770) was then applied to each well and the plate was
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well should be between two and three at an absorbance
of 405 nm. The optical density was then determined at a
wavelength between 405–570 nm, and a final cytokine
concentration was determined in pg/mL.Statistical analysis
Cytokine and Ang-1/2 data were broken down into vari-
ous categories for analysis. The primary focus was on
significant differences between FB and CB data using an
unpaired student’s t-test. Additional comparisons were
made for the data set based on patient travel history, age,
gender, and species of infection. Samples for which cyto-
kine or Ang-1/2 testing did not yield data due to tech-
nical difficulties were excluded. Each comparison was
completed using the student’s unpaired t-test to assess
significant differences between the related data sets
defined by a p value <0.05 (Additional file 1: Table S1).
The values are reported as mean ± SD. Data analysis was
completed using GraphPad Prism (La Jolla, CA, USA)
graphing software.Results
Immune response by birth status
The cytokine levels indicated a variety of significant dif-
ferences when the data was analysed by CB vs FB, gen-
der, travel history, and ages grouped by 0–18, 19–55,
and 55+ (Table 2). When divided into CB and FB
groups, a significantly higher level of IL-12 (p40) was
found in CB travellers than in FB travellers (p< 0.01)
(Figure 1). When the P. falciparum-infected patients
were examined alone, the CB travellers also had a sig-
nificantly higher level of IL-12 (p40) compared to FB
travellers (p =<0.01). A significantly higher level of EGF
(p = 0.0315) was found to exist in FB compared to CB
travellers (Figure 1).Figure 1 Canadian-born (CB) and Foreign-born (FB) significant differe
between CB and FB travellers. Each coloured circle represents a single patie
concentration. Data sets are compared to one another by arrows spanningImmune response by age and species
When grouped by ages, P. vivax infections indicated a
tendency for older adults to have a more robust immune
response than younger adults for two different cytokines.
Those individuals aged 55 and over demonstrated a
higher level of IL-6 (p= 0.0366), and M-CSF (p= 0.0433),
than those aged 19–55 (Figure 2).
Cytokine responses for individuals infected with P. ovale,
P. malariae, P. vivax, and P. falciparum were compared
and significant differences in the mean level of several
cytokines were found when looking at all patient data,
comparisons of CB patients only, and comparisons FB
patients only. Patients infected with P. vivax had higher
levels of MCP-1 (p=<0.0001) and M-CSF (p=<0.0001)
than patients infected with P. falciparum. Patients infected
with P. vivax had higher levels of IL-12 (p40) (p=0.0478)
than patients infected with P. ovale. CB patients infected
with P. vivax also had higher levels of MCP-1
(p=<0.0001), and M-CSF (p=0.0367), when compared to
CB patients infected with P. falciparum. FB patients
infected with P. vivax had higher levels for MCP-1
(p=0.0020), M-CSF (p=<0.0001), and also IL-12(p40)
(p = 0.0467), compared to FB patients infected with
P. falciparum (Figure 3).Immune response by region of travel
Levels of IFN-γ (p= 0.0414) and IL-6 (p= 0.0426) were
significantly lower in patients who travelled to West Af-
rica compared to those who had travelled to other
regions in Africa (Figure 4).Endothelium activation based on angiopoietin levels
The Ang-1/2 concentrations showed no significant differ-
ence between FB and CB patient groups. Additional ana-
lysis by gender, travel history, and ages grouped by 0–18,
19–55, and 55+, showed no significant differences fornces. Significant differences for IL-12 (p40) and EGF were observed
nt, with a horizontal line through each data set indicating the mean
between them along with an asterix. See Table 2 for p values.
Figure 2 Age-based significant differences. Significant differences for IL-6 and M-CSF were observed between 19–54 year olds and those 55
and older who were infected with Plasmodium vivax. Each coloured circle represents a single patient, with a horizontal line through each data set
indicating the mean concentration. Data sets are compared to one another by arrows spanning between them along with an asterix. See Table 2
for p values.
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A significantly higher level of Ang-2 (p< 0.01) was
observed in patients infected with P. falciparum, compared
to those infected with P. vivax. The Ang-2 levels were also
significantly different (p=0.0218) between the FB patients
infected with each species, with a higher mean present for
FB P. falciparum than for FB P. vivax (Figure 3).Figure 3 Species-based significant differences. Significant differences fo
patients infected with Plasmodium vivax and Plasmodium falciparum, and a
infected with P. vivax and Plasmodium ovale. Each coloured circle represent
indicating the mean concentration. Data sets are compared to one anothe
for p values.Discussion
This study was conducted on returning travellers who
contracted malaria in order to evaluate the cytokine, chemo-
kine, and endothelial activation response in human infection.
We hypothesized that in cities like Toronto travellers
infected with malaria who are CB will elaborate a different
immune response to those who are FB. This response wasr IL-12 (p40), MCP-1, M-CSF, and Ang-2 were observed between
significant difference was noted for IL-12 (p40) between patients
s a single patient, with a horizontal line through each data set
r by arrows spanning between them along with an asterix. See Table 2
Figure 4 Significant differences based on travel history. Significant differences for IFN-γ and IL-6 were observed between patients who
travelled to west Africa and those who travelled in a different region of Africa. Each coloured circle represents a single patient, with a horizontal
line through each data set indicating the mean concentration. Data sets are compared to one another by arrows spanning between them along
with an asterix. See Table 2 for p values.
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ive factors for those who had been previously exposed. The
data highlights that IL-12 (p40) and EGF are potential mar-
kers of disease severity. It was noted that IL-12 (p40) was
significantly increased and EGF significantly decreased in
CB. If CB are more vulnerable to severe diseases as has been
suspect clinically, then high IL-12 (p40) and low EGF may
predict worse outcomes. Consistent with this observation,
IL-12 (p40) is a pro-inflammatory cytokine produced by
mononuclear phagocytes that activates T-helper 1 cells
(Th1) and is important for assisting in innate immuneTable 2 Statistical summary for comparisons made in this stu
Analysis Marker Dat
CB vs FB Il-12(p40) CB n
EGF CB n
Pf CB vs Pf FB IL-12(p40) CB n
Pv Age: 55+ vs 19-54 IL-6 55+
MCSF 55+
Species: Pf vs Pv MCP-1 Pf n
M-CSF Pf n
Angiopoietin 2 Pf n
Species: Pv vs Po IL-12 (p40) Pv n
Species: Pf CB vs Pv CB MCP-1 Pf C
MCSF Pf C
Species: Pf FB vs Pv FB MCP-1 Pf F
M-CSF Pf F
IL-12 (p40) Pf F
Angiopoietin 2 Pf F
Travel: West Africa vs other African regions IFN-γ Wes
IL-6 Wes
Only data for significant differences are shown. Sample size, mean values with stand
showed significant differences. All other cytokine comparisons were not significantlresponses against intracellular microbes [14]. However, some
studies have shown elevated plasma levels of IL-12 (p40)
attributed to mild cases of malaria, with low levels being
associated with severe malaria [14,21]. Other studies counter
these claims and indicate elevated levels have been seen in
individuals with severe malaria in certain Asian populations
[13,22]. Additionally, a pre-disposition to severe malaria has
been shown to be caused by certain promoter variants that
cause an increase in IL-12 production [22,23]. The findings
provide support to the idea that IL-12 is more abundant in
severe malaria. Further studies into the genetic properties ofdy
a Set 1 Mean Set 1 Data Set 2 Mean Set 2 P Value
= 57 70.39 ± 9.95 FB n = 87 36.24 ± 3.28 <0.01
= 37 9.477 ± 1.52 FB n = 60 14.82 ± 1.68 0.0315
= 46 70.31 ± 11.79 FB n = 42 31.53 ± 4.09 <0.01
n = 10 858.8 ± 454.3 19-54 n= 21 134.7 ± 82.59 0.0366
n = 10 45.66 ± 8.25 19-54 n= 23 31.21 ± 2.82 0.0433
= 86 63.78 ± 11.44 Pv n = 38 392.5 ± 95.45 <0.01
= 69 17.61 ± 2.05 Pv n = 38 35.6 ± 3.38 <0.01
= 96 1120 ± 196.5 Pv n = 59 336.5 ± 88.21 <0.01
= 38 51.4 ± 6.76 Po n= 12 26.4 ± 3.73 0.0478
B n= 46 74.74 ± 16.63 Pv CB n= 8 563.4 ± 233.2 <0.01
B n= 39 19.59 ± 2.89 Pv CB n= 8 34.37 ± 5.59 0.0367
B n = 40 51.18 ± 15.43 Pv FB n = 30 347 ± 104.3 <0.01
B n = 30 15.32 ± 1.87 Pv FB n = 30 35.3 ± 4.05 <0.01
B n = 42 31.53 ± 4.09 Pv FB n = 30 47 ± 7.01 0.0467
B n = 48 1033 ± 296.6 Pv FB n = 49 310.8 ± 97.81 <0.01
t n = 27 11.88 ± 1.98 Other n = 12 22.5 ± 6.16 0.0414
t n = 22 31.58 ± 6.28 Other n = 12 120.1 ± 56.27 0.0426
ard deviation, and the p-value are displayed for all data comparisons that
y different.
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in determining the connections between this study and the
findings of others.
EGF binds to the epidermal growth factor receptor
(EGFR) where it plays a key role in regulating cellular
differentiation, proliferation, and survival [24]. EGF-like
domains on P. falciparum surface proteins have been
studied in great detail for vaccine research [16,24,25],
but studies looking at the relationship between EGF
levels circulating in the body and malaria infection have
not been explored in any detail. The findings indicate a
tendency for FB individuals to have a significantly
higher level of circulating plasma EGF than CB indivi-
duals, but further research will need to be completed to
determine the significance of this result and the poten-
tial relevance increased levels may have in protecting
against severe disease.
Studies focusing on older adults [26], as well as African-
based epidemiological data for children [27] show a ten-
dency for these groups to be stricken with malaria more
frequently than other age groups, with mortality often at
the highest among young children. The results indicated
that in P. vivax infections, adults over age 55 had more
pronounced IL-6 and M-CSF production. IL-6 is a pro-in-
flammatory cytokine. It is produced by numerous cell
types including monocytes, endothelial cells and fibro-
blasts [28] and has a variety of biological roles, including
the stimulation of B and T cell differentiation [29]. IL-6
has been shown to be elevated in Mali children with se-
vere P. falciparum malaria [30], in a study of severe cases
of malaria among 40 adults aged 21–65 [28], and has been
found elevated in patients with cerebral malaria and renal
failure [31]. The findings corroborate these studies, sug-
gesting further potential of IL-6 as a marker of disease se-
verity. It was surprising to not find the same result in P.
falciparum infections, where the role of IL-6 was expected
to be more pronounced.
Macrophage colony-stimulating factor (M-CSF)
enhances macrophage activity, and it has been suggested
that when elevated in malaria, it may lead to an increase
in macrophage-mediated platelet destruction [17]. Ele-
vated levels of M-CSF have been attributed to severe
cases of P. falciparum malaria, where platelet destruction
and the release of P-selectin plays a role in thrombocyto-
paenia associated with severe disease [17]. M-CSF has
also been noted to be elevated in P. vivax cases [17], so
the results indicating a higher level of M-CSF in older
patients with P. vivax infection appear reasonable. It was
noted that when all patient data was divided by species
of infection, P. vivax had a higher mean cytokine re-
sponse for M-CSF than P. falciparum. This corresponds
for the tendency of P. vivax to elicit a stronger immune
response in patients [32], though this is not necessarily a
marker of severity, but is a marker of interest. Thesignificant difference was also seen between M-CSF of
just FB patients with P. vivax compared to P. falciparum,
as well as just CB patients.
Monocyte chemo-attractant protein 1 (MCP-1) is
required for migration of monocytes and macrophages
to sites of inflammation [33], and has been associated
with several neuro-inflammatory, and other inflamma-
tory diseases, including HIV-1 encephalitis, and rheuma-
toid arthritis [34,35]. MCP-1 studies previously showed it
to have no association with severe and cerebral malaria
in P. falciparum-infected patients from Thailand and
India [15,36]. The results indicated a substantially higher
level of MCP-1 in patients infected with P. vivax com-
pared to P. falciparum within the full data set, and in
comparisons of just FB individuals, and just CB indivi-
duals. This finding again corresponds to the tendency of
P. vivax to have a greater inflammatory response than P.
falciparum, as does the results with just FB blood sam-
ples where the P. vivax patients again had a higher level
of IL-12 (p40) than P. falciparum patients. The increased
levels of circulating IL-12 (p40) in P. vivax compared to
P. ovale again attests to the substantial inflammatory re-
sponse associated with P. vivax.
Infections obtained through travel to different areas of
Africa also showed a significant difference in patient im-
mune response. A substantial amount of the P. falcip-
arum blood samples were from travellers who had been
to Western Africa, with most having visited Ghana and
Nigeria. All those individuals who had contracted mal-
aria in Western African countries (which included Ni-
geria and Ghana), were grouped and compared against
travellers who were known to have been in other regions
of Africa. Significantly lower levels of IL-6 and IFN-γ
were found in the Western Africa subset. One study has
indicated that there can be reductions in total cases of
severe malaria with increasing transmission rates [37],
possibly indicating increased transmission of malaria in
Western Africa triggers a lower intensity immune re-
sponse. An additional possibility could be the presence
of unique strains in West Africa triggering a different
immune response compared to other African strains.
Of the cytokines that were found to be associated with
travel, Il-6 has been shown to often be elevated in severe
cases of malaria [28,30,31] as mentioned previously. It was
also observed to be a contributor to disease outcome in
non-endemic areas of India compared to endemic areas
[38]. Studies on children in Sudan, an area of unstable
malaria transmission, indicate a tendency for severe cases
of P. falciparum malaria to have elevated levels of IFN- γ
[39]; this is also observed in severe cases of P. falciparum
malaria in India among patients aged five to 75 [13]. Stud-
ies on P. vivax-infected patients from the Brazilian Ama-
zon indicate plasma levels of IFN- γ increase linearly with
a gradual augmentation of disease severity [40].
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serum levels in malaria infections
Ang-2 levels have been reported to be elevated in cases
of complicated severe malaria compared to uncompli-
cated malaria [12,19]. Ang-2 primes vascular endothelial
cells to exogenous cytokines, and at high concentrations
can trigger vascular permeability [41,42]. The results in-
dicate that in P. falciparum infections, a higher level of
Ang-2 is present than in P. vivax infections. These find-
ings appeared in a comparison of all the patient data, as
well as in a comparison of just FB patients with P.
falciparum compared to FB with P. vivax. P. falciparum
is generally considered to be more virulent than other
causes of malaria, and has been observed to more com-
monly lead to severe cases of malaria [43]. Higher levels
of Ang-2 in P. falciparum infections are consistent with
this endothelium activation factor as Ang-2 and P. falcip-
arum are both associated with more severe disease
instances. A previous study reported that Ang-2 was
more strongly elevated in the peripheral blood of indivi-
duals with P. vivax malaria compared to individuals with
P. falciparum infection [44], which corresponds to its
tendency to trigger a stronger cytokine response in
infected patients.
Conclusion
The significantly higher mean levels of IL-12 (p40) and
significantly lower levels of EGF found in CB travellers
may serve to be useful prognostic markers of disease se-
verity and help guide clinical management upon their re-
turn. IL-6 and M-CSF in older adults, MCP-1, IL-12
(p40) and M-CSF in P. vivax-infected patients, and Ang-
2 in P. falciparum-infected patients may also prove use-
ful in understanding age-associated and species-specific
host immune responses. Regional differences in host im-
mune response to malaria infection within the same spe-
cies (P. falciparum) may be related to unique strains
circulating in West Africa.
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